CN104093715B - 4‑(苯并咪唑‑2‑基)‑噻唑化合物及相关氮杂衍生物 - Google Patents
4‑(苯并咪唑‑2‑基)‑噻唑化合物及相关氮杂衍生物 Download PDFInfo
- Publication number
- CN104093715B CN104093715B CN201380007926.7A CN201380007926A CN104093715B CN 104093715 B CN104093715 B CN 104093715B CN 201380007926 A CN201380007926 A CN 201380007926A CN 104093715 B CN104093715 B CN 104093715B
- Authority
- CN
- China
- Prior art keywords
- methyl
- thiazol
- group
- piperazin
- ethanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C(C)*(C(*)C*(*(C)C)C(N=C(*)*1)=C1C(**)=*C(C=CC=C1)C1=C)C(C*)=O Chemical compound C*C(C)*(C(*)C*(*(C)C)C(N=C(*)*1)=C1C(**)=*C(C=CC=C1)C1=C)C(C*)=O 0.000 description 4
- OCFHKEUTKJHZCY-UHFFFAOYSA-N CN1NCc2c1nccc2 Chemical compound CN1NCc2c1nccc2 OCFHKEUTKJHZCY-UHFFFAOYSA-N 0.000 description 1
- XIPBLKOJUBEBEC-UHFFFAOYSA-N C[n](cc1)c2c1ccc(Cl)n2 Chemical compound C[n](cc1)c2c1ccc(Cl)n2 XIPBLKOJUBEBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOCBNCKNQJAFL-UHFFFAOYSA-N C[n](cc1)c2c1cccn2 Chemical compound C[n](cc1)c2c1cccn2 ZVOCBNCKNQJAFL-UHFFFAOYSA-N 0.000 description 1
- GGPMDNQTEJJLMQ-UHFFFAOYSA-N C[n](cc1)c2c1ccnc2 Chemical compound C[n](cc1)c2c1ccnc2 GGPMDNQTEJJLMQ-UHFFFAOYSA-N 0.000 description 1
- LUKGSNKDUABBRT-UHFFFAOYSA-N C[n](cc1)c2c1ccnc2Cl Chemical compound C[n](cc1)c2c1ccnc2Cl LUKGSNKDUABBRT-UHFFFAOYSA-N 0.000 description 1
- ZBBUBTIPIAXRQN-PLNGDYQASA-N C[n]1c(N)c(/C=C\C=C)nc1 Chemical compound C[n]1c(N)c(/C=C\C=C)nc1 ZBBUBTIPIAXRQN-PLNGDYQASA-N 0.000 description 1
- FGYADSCZTQOAFK-UHFFFAOYSA-N C[n]1c(cccc2)c2nc1 Chemical compound C[n]1c(cccc2)c2nc1 FGYADSCZTQOAFK-UHFFFAOYSA-N 0.000 description 1
- PWIGGZLIWJBPRY-UHFFFAOYSA-N C[n]1c(nccc2)c2c(Cl)c1 Chemical compound C[n]1c(nccc2)c2c(Cl)c1 PWIGGZLIWJBPRY-UHFFFAOYSA-N 0.000 description 1
- QLFIVKKMICXCNV-UHFFFAOYSA-N C[n]1nc2ncccc2c1 Chemical compound C[n]1nc2ncccc2c1 QLFIVKKMICXCNV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2012/050489 | 2012-02-02 | ||
| IBPCT/IB2012/050489 | 2012-02-02 | ||
| PCT/IB2013/050870 WO2013114332A1 (en) | 2012-02-02 | 2013-02-01 | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104093715A CN104093715A (zh) | 2014-10-08 |
| CN104093715B true CN104093715B (zh) | 2017-04-26 |
Family
ID=48014121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380007926.7A Expired - Fee Related CN104093715B (zh) | 2012-02-02 | 2013-02-01 | 4‑(苯并咪唑‑2‑基)‑噻唑化合物及相关氮杂衍生物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9266876B2 (enExample) |
| EP (1) | EP2809668B1 (enExample) |
| JP (1) | JP6073931B2 (enExample) |
| KR (1) | KR101800607B1 (enExample) |
| CN (1) | CN104093715B (enExample) |
| AU (1) | AU2013216354B2 (enExample) |
| BR (1) | BR112014018714A8 (enExample) |
| CA (1) | CA2861020C (enExample) |
| CL (1) | CL2014002048A1 (enExample) |
| EA (1) | EA027595B1 (enExample) |
| ES (1) | ES2632237T3 (enExample) |
| IL (1) | IL233872A (enExample) |
| MX (1) | MX352181B (enExample) |
| MY (1) | MY170524A (enExample) |
| NZ (1) | NZ629795A (enExample) |
| PH (1) | PH12014501540B1 (enExample) |
| PL (1) | PL2809668T3 (enExample) |
| SG (1) | SG11201404144PA (enExample) |
| UA (1) | UA113638C2 (enExample) |
| WO (1) | WO2013114332A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2671323T3 (es) * | 2013-07-22 | 2018-06-06 | Idorsia Pharmaceuticals Ltd | Derivados 1¿(piperazin¿1¿il)¿2¿([1,2,4]triazol¿1¿il)¿etanona |
| JP6510539B2 (ja) | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
| AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| AR103399A1 (es) * | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| PL3245203T3 (pl) * | 2015-01-15 | 2019-05-31 | Idorsia Pharmaceuticals Ltd | Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3 |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2018011265A1 (en) | 2016-07-13 | 2018-01-18 | Idorsia Pharmaceuticals Ltd | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators |
| FR3067028B1 (fr) | 2017-06-06 | 2019-07-12 | Adpuerivitam | Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central |
| MX2023001758A (es) * | 2020-08-11 | 2023-04-11 | Univ Michigan State | Potenciadores de proteasoma y usos de los mismos. |
| WO2022093552A2 (en) * | 2020-10-16 | 2022-05-05 | Saint Louis Univeristy | Rev-erb agonists |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007064553A2 (en) * | 2005-11-29 | 2007-06-07 | Merck & Co., Inc. | Thiazole derivatives as cxcr3 receptor modulators |
| WO2007070433A2 (en) * | 2005-12-12 | 2007-06-21 | Merck & Co., Inc. | 2-arylthiazole derivatives as cxcr3 receptor modulators |
| CN101163693A (zh) * | 2005-02-18 | 2008-04-16 | 阿斯利康(瑞典)有限公司 | 抗菌哌啶衍生物 |
| WO2009055514A2 (en) * | 2007-10-23 | 2009-04-30 | E. I. Du Pont De Nemours And Company | Fungicidal mixtures |
| CN101558066A (zh) * | 2006-08-17 | 2009-10-14 | 阿斯利康(瑞典)有限公司 | 具有抗菌活性的吡咯衍生物 |
| US20100280028A1 (en) * | 2009-04-27 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60205465T2 (de) | 2001-01-23 | 2006-04-20 | Eli Lilly And Co., Indianapolis | Piperazinderivate als agonisten des melanocortin-rezeptors |
| HUP0401544A2 (hu) | 2001-03-02 | 2004-12-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
| GB0229618D0 (en) * | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| WO2005035534A1 (ja) | 2003-10-08 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| WO2005042516A2 (en) | 2003-10-22 | 2005-05-12 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
| US20060276465A1 (en) | 2003-12-26 | 2006-12-07 | Eisai R&D Management Co., Ltd. | 1,2-di(cyclic) substituted benzene compounds |
| MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
| EP1856097B1 (en) | 2005-02-16 | 2012-07-11 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| WO2006091428A2 (en) | 2005-02-16 | 2006-08-31 | Schering Corporation | Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
| JP2008530220A (ja) | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、ピラジニルで置換されたピペラジン−ピペリジン |
| US7566718B2 (en) | 2005-02-16 | 2009-07-28 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity |
| KR20070107046A (ko) | 2005-02-16 | 2007-11-06 | 쉐링 코포레이션 | Ｃｘｃｒ3 길항제 활성을 지닌 헤테로사이클릭 치환된피페라진 |
| CN101146793A (zh) | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
| WO2006088836A2 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| WO2007002742A1 (en) | 2005-06-28 | 2007-01-04 | Pharmacopeia, Inc. | Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders |
| US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
| TW200738701A (en) | 2005-07-26 | 2007-10-16 | Du Pont | Fungicidal carboxamides |
| US7781437B2 (en) | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
| WO2007076318A2 (en) | 2005-12-21 | 2007-07-05 | Smithkline Beecham Corporation | Camphor-derived cxcr3 antagonists |
| WO2007100610A2 (en) | 2006-02-23 | 2007-09-07 | Merck & Co., Inc. | Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators |
| PE20071144A1 (es) | 2006-03-21 | 2008-01-10 | Schering Corp | COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3) |
| FR2903405B1 (fr) | 2006-07-04 | 2011-09-09 | Pasteur Institut | Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications |
| KR20090043512A (ko) | 2006-07-14 | 2009-05-06 | 쉐링 코포레이션 | Ｃｘｃｒ3 길항제 활성을 갖는 헤테로사이클릭 치환된 피페라진 화합물 |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| CA2673231A1 (en) | 2006-12-22 | 2008-07-03 | Schering Corporation | Heterocyclic compounds with cxcr3 antagonist activity |
| CA2669412A1 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| WO2008091580A2 (en) | 2007-01-25 | 2008-07-31 | E. I. Du Pont De Nemours And Company | Fungicidal amides |
| EP2185154A2 (en) | 2007-08-03 | 2010-05-19 | Schering Corporation | Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines |
| EP2234971A1 (en) | 2007-12-18 | 2010-10-06 | Schering Corporation | Process and intermediates for the synthesis of heterocyclic substituted piperazines with cxcr3 antagonist activity |
| EP2242757B1 (en) * | 2008-01-09 | 2012-08-01 | Array Biopharma, Inc. | Pyrazolopyridines as kinase inhibitors |
| JP5535941B2 (ja) | 2008-01-25 | 2014-07-02 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺菌性アミド |
| JP5529044B2 (ja) | 2008-01-25 | 2014-06-25 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺菌性複素環化合物 |
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
| WO2009132785A1 (de) | 2008-04-30 | 2009-11-05 | Bayer Cropscience Aktiengesellschaft | Thiazol-4-carbonsäureester und thioester als pflanzenschutzmittel |
| BRPI0918517B8 (pt) * | 2008-09-11 | 2021-05-25 | Chemocentryx Inc | composto, composição farmacêutica, e, uso de um composto |
| BRPI0920767B1 (pt) | 2008-10-01 | 2018-07-17 | Bayer Intellectual Property Gmbh | tiazóis substituídos por heterociclila como agentes protetores de cultura, seus usos e seus processos de preparação, composições e seu processo de preparação, e método para combate a fungos nocivos fitopatogênicos |
| KR101052065B1 (ko) | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
| EP2358709B1 (en) | 2008-12-02 | 2014-01-22 | E. I. du Pont de Nemours and Company | Fungicidal heterocyclic compounds |
| JP2012511525A (ja) | 2008-12-11 | 2012-05-24 | バイエル・クロップサイエンス・アーゲー | 植物保護剤としてのチアゾリルオキシムエーテルおよびヒドラゾン |
| US8362249B2 (en) | 2009-04-27 | 2013-01-29 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| EP2272846A1 (de) | 2009-06-23 | 2011-01-12 | Bayer CropScience AG | Thiazolylpiperidin Derivate als Fungizide |
| UA107938C2 (en) | 2009-08-12 | 2015-03-10 | Syngenta Participations Ag | Heterocycles with microbicidal properties |
| US8557821B2 (en) | 2009-08-12 | 2013-10-15 | Syngenta Crop Protection, Llc | Microbiocidal heterocycles |
| WO2011051243A1 (en) | 2009-10-29 | 2011-05-05 | Bayer Cropscience Ag | Active compound combinations |
| KR20120101019A (ko) | 2009-10-30 | 2012-09-12 | 바이엘 크롭사이언스 아게 | 헤테로아릴피페리딘 및 -피페라진 유도체 |
| EP2516426B1 (de) | 2009-12-21 | 2015-09-16 | Bayer CropScience AG | Bis(difluormethyl)pyrazole als fungizide |
| WO2011084985A1 (en) | 2010-01-07 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
| EP2563786B1 (de) | 2010-04-28 | 2016-11-02 | Bayer Intellectual Property GmbH | Ketoheteroarylpiperidin und -piperazin Derivate als Fungizide |
| US8815775B2 (en) | 2010-05-18 | 2014-08-26 | Bayer Cropscience Ag | Bis(difluoromethyl)pyrazoles as fungicides |
| CN102933577B (zh) | 2010-05-20 | 2014-08-06 | 纳幕尔杜邦公司 | 杀真菌的肟和腙 |
| CN103025723A (zh) | 2010-05-27 | 2013-04-03 | 拜尔农作物科学股份公司 | 作为杀真菌剂的吡啶基羧酸衍生物 |
| US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
| US20140005224A1 (en) | 2010-10-27 | 2014-01-02 | Bayer Intellectual Property Gmbh | Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides |
| EP2643312B1 (en) | 2010-11-25 | 2014-09-10 | Syngenta Participations AG | Microbicidal heterocycles |
| CN103384470A (zh) | 2010-12-17 | 2013-11-06 | 纳幕尔杜邦公司 | 杀真菌偶氮环酰胺 |
| MX352307B (es) | 2011-02-01 | 2017-11-17 | Bayer Ip Gmbh | Derivados de heteroarilpiperidina y -piperazina como fungicidas. |
| EP2673264A1 (en) | 2011-02-10 | 2013-12-18 | Syngenta Participations AG | Microbiocidal pyrazole derivatives |
| EP2673272A1 (en) | 2011-02-10 | 2013-12-18 | Syngenta Participations AG | Microbiocidal pyrazole derivatives |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103827112A (zh) | 2011-09-15 | 2014-05-28 | 拜耳知识产权有限责任公司 | 作为杀真菌剂的哌啶吡唑 |
| EP2768828A1 (en) | 2011-10-18 | 2014-08-27 | Syngenta Participations AG | Microbiocidal pyrazole derivatives |
| CN103889982A (zh) | 2011-10-18 | 2014-06-25 | 先正达参股股份有限公司 | 杀微生物的吡唑衍生物 |
| US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
| IN2012DE00621A (enExample) | 2012-03-02 | 2015-07-17 | Syngenta Participations Ag | |
| WO2013127784A1 (en) | 2012-03-02 | 2013-09-06 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
| US10035790B2 (en) | 2012-10-19 | 2018-07-31 | Exelixis, Inc. | RORγ modulators |
| WO2014075874A1 (en) | 2012-11-13 | 2014-05-22 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
| WO2014075873A1 (en) | 2012-11-13 | 2014-05-22 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
-
2013
- 2013-02-01 CA CA2861020A patent/CA2861020C/en active Active
- 2013-02-01 US US14/376,307 patent/US9266876B2/en active Active
- 2013-02-01 UA UAA201409420A patent/UA113638C2/uk unknown
- 2013-02-01 CN CN201380007926.7A patent/CN104093715B/zh not_active Expired - Fee Related
- 2013-02-01 MX MX2014009355A patent/MX352181B/es active IP Right Grant
- 2013-02-01 EP EP13712913.6A patent/EP2809668B1/en active Active
- 2013-02-01 ES ES13712913.6T patent/ES2632237T3/es active Active
- 2013-02-01 AU AU2013216354A patent/AU2013216354B2/en not_active Ceased
- 2013-02-01 KR KR1020147024508A patent/KR101800607B1/ko not_active Expired - Fee Related
- 2013-02-01 JP JP2014555374A patent/JP6073931B2/ja not_active Expired - Fee Related
- 2013-02-01 SG SG11201404144PA patent/SG11201404144PA/en unknown
- 2013-02-01 NZ NZ629795A patent/NZ629795A/en not_active IP Right Cessation
- 2013-02-01 EA EA201400854A patent/EA027595B1/ru not_active IP Right Cessation
- 2013-02-01 PL PL13712913T patent/PL2809668T3/pl unknown
- 2013-02-01 BR BR112014018714A patent/BR112014018714A8/pt not_active IP Right Cessation
- 2013-02-01 WO PCT/IB2013/050870 patent/WO2013114332A1/en not_active Ceased
- 2013-02-01 MY MYPI2014702122A patent/MY170524A/en unknown
-
2014
- 2014-07-03 PH PH12014501540A patent/PH12014501540B1/en unknown
- 2014-07-30 IL IL233872A patent/IL233872A/en not_active IP Right Cessation
- 2014-07-31 CL CL2014002048A patent/CL2014002048A1/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101163693A (zh) * | 2005-02-18 | 2008-04-16 | 阿斯利康(瑞典)有限公司 | 抗菌哌啶衍生物 |
| WO2007064553A2 (en) * | 2005-11-29 | 2007-06-07 | Merck & Co., Inc. | Thiazole derivatives as cxcr3 receptor modulators |
| WO2007070433A2 (en) * | 2005-12-12 | 2007-06-21 | Merck & Co., Inc. | 2-arylthiazole derivatives as cxcr3 receptor modulators |
| CN101558066A (zh) * | 2006-08-17 | 2009-10-14 | 阿斯利康(瑞典)有限公司 | 具有抗菌活性的吡咯衍生物 |
| WO2009055514A2 (en) * | 2007-10-23 | 2009-04-30 | E. I. Du Pont De Nemours And Company | Fungicidal mixtures |
| US20100280028A1 (en) * | 2009-04-27 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013216354B2 (en) | 2017-08-31 |
| NZ629795A (en) | 2016-06-24 |
| KR20140120364A (ko) | 2014-10-13 |
| PH12014501540A1 (en) | 2014-09-22 |
| JP2015506957A (ja) | 2015-03-05 |
| MY170524A (en) | 2019-08-09 |
| EP2809668A1 (en) | 2014-12-10 |
| PH12014501540B1 (en) | 2014-09-22 |
| EA201400854A1 (ru) | 2015-04-30 |
| WO2013114332A1 (en) | 2013-08-08 |
| MX2014009355A (es) | 2014-09-01 |
| JP6073931B2 (ja) | 2017-02-01 |
| ES2632237T3 (es) | 2017-09-12 |
| UA113638C2 (xx) | 2017-02-27 |
| HK1203939A1 (en) | 2015-11-06 |
| SG11201404144PA (en) | 2014-10-30 |
| MX352181B (es) | 2017-11-13 |
| BR112014018714A2 (enExample) | 2017-06-20 |
| CL2014002048A1 (es) | 2014-11-14 |
| EA027595B1 (ru) | 2017-08-31 |
| PL2809668T3 (pl) | 2018-02-28 |
| AU2013216354A1 (en) | 2014-09-25 |
| CN104093715A (zh) | 2014-10-08 |
| BR112014018714A8 (pt) | 2017-12-26 |
| KR101800607B1 (ko) | 2017-11-23 |
| EP2809668B1 (en) | 2017-04-12 |
| IL233872A (en) | 2017-05-29 |
| CA2861020A1 (en) | 2013-08-08 |
| CA2861020C (en) | 2018-07-17 |
| US9266876B2 (en) | 2016-02-23 |
| US20140371204A1 (en) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104093715B (zh) | 4‑(苯并咪唑‑2‑基)‑噻唑化合物及相关氮杂衍生物 | |
| US11739098B2 (en) | Substituted indole compounds | |
| USRE49880E1 (en) | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | |
| AU2011240808B2 (en) | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases | |
| TWI471326B (zh) | 作為ｃＦＭＳ抑制劑之經取代之Ｎ－（１Ｈ－吲唑－４－基）咪唑［１，２－ａ］吡啶－３－羧醯胺化合物 | |
| HUE025416T2 (en) | Substituted n- (1H-indazol-4-yl) imidazo [1,2-a] pyridine-3-carboxamide compounds as Type III receptor tyrosine kinase inhibitors | |
| US20240025906A1 (en) | Kinase modulators and methods of use thereof | |
| CN117836297A (zh) | (s)-1-(5-((吡啶-3-基)硫代)吡嗪-2-基)-4'h,6'h-螺[哌啶-4,5'-吡咯并[1,2-b]吡唑]-4'-胺衍生物和类似化合物作为shp2抑制剂用于例如癌症的治疗 | |
| CA3194376A1 (en) | Hsd17b13 inhibitors and uses thereof | |
| CA3117510A1 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| CA3236550A1 (en) | Spirotricycle ripk1 inhibitors and methods of uses thereof | |
| JP2024539633A (ja) | 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用 | |
| HK1203939B (en) | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | |
| TW202523301A (zh) | Ripk1抑制劑及使用方法 | |
| AU2015201991A1 (en) | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171009 Address after: Swiss A Skei Weil Patentee after: ACTELION PHARMACEUTICALS LTD. Address before: Swiss A Skei Weil Patentee before: Actelion Pharmaceuticals Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170426 |